文献速递肝病

TIPE1通过抑制ASK1多泛素化减轻肝脏脂肪变性、炎症和纤维化

TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.
PubMed 文献 · Hepatology · 2021-08-21

该研究探讨TIPE1在非酒精性脂肪性肝炎(NASH)中的作用。肝细胞特异性敲除TIPE1加重饮食诱导的肝脏脂肪变性、炎症和纤维化及全身代谢紊乱,而过表达TIPE1则显著阻止这些异常进展。机制上TIPE1直接结合ASK1并抑制其TRAF6催化的多泛素化激活,从而抑制下游JNK和p38信号通路。NAFLD患者肝脏中TIPE1表达显著降低,提示其可能成为治疗靶点。

要点

  • 肝细胞TIPE1缺失加重NASH进展,过表达则减轻病变。
  • TIPE1直接结合ASK1并抑制TRAF6催化的多泛素化激活。
  • NAFLD患者肝脏TIPE1表达显著降低,提示治疗潜力。

核心结论

  • TIPE1通过直接结合ASK1并抑制其TRAF6催化的多泛素化,保护肝脏免受脂肪变性、炎症和纤维化。
  • 靶向TIPE1可能是NAFLD治疗的有前景的方法。

研究设计与样本

  • 研究采用肝细胞特异性TIPE1敲除和过表达小鼠模型,观察饮食诱导NASH过程中的肝脏表型及代谢变化。
  • 机制研究探讨TIPE1与ASK1的相互作用及其对TRAF6催化的多泛素化和下游JNK、p38信号通路的影响。
  • 检测NAFLD患者肝脏中TIPE1的表达水平。

主要发现

  • 肝细胞特异性敲除TIPE1加重饮食诱导的肝脏脂肪变性、炎症和纤维化以及全身代谢紊乱。
  • 肝细胞特异性过表达TIPE1显著阻止上述异常进展。
  • TIPE1直接与ASK1相互作用,抑制代谢挑战下TRAF6催化的ASK1多泛素化激活,进而抑制下游JNK和p38信号通路。
  • NAFLD患者肝脏中TIPE1表达显著降低。

临床怎么用

  • TIPE1可能作为NAFLD及相关代谢疾病的潜在治疗靶点。
  • 肝细胞TIPE1表达水平或可用于评估NAFLD疾病进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Characterized by hepatocyte steatosis, inflammation, and fibrosis, NASH is a complicated process that contributes to end-stage liver disease and, eventually, HCC. TNF-α-induced protein 8-like 1 (TIPE1), a new member of the TNF-α-induced protein 8 family, has been explored in immunology and oncology research; but little is known about its role in metabolic diseases. APPROACH AND RESULTS: Here, we show that hepatocyte-specific deletion of TIPE1 exacerbated diet-induced hepatic steatosis, inflammation, and fibrosis as well as systemic metabolic disorders during NASH pathogenesis. Conversely, hepatocyte-specific overexpression of TIPE1 dramatically prevented the progression of these abnormalities. Mechanically, TIPE1 directly interacted with apoptosis signal-regulating kinase 1 (ASK1) to suppress its TNF receptor-associated factor 6 (TRAF6)-catalyzed polyubiquitination activation upon metabolic challenge, thereby inhibiting the downstream c-Jun N-terminal kinase and p38 signaling pathway. Importantly, dramatically reduced TIPE1 expression was observed in the livers of patients with NAFLD, suggesting that TIPE1 might be a promising therapeutic target for NAFLD and related metabolic diseases. CONCLUSIONS: TIPE1 protects against hepatic steatosis, inflammation, and fibrosis through directly binding ASK1 and restraining its TRAF6-catalyzed polyubiquitination during the development of NASH. Therefore, targeting TIPE1 could be a promising therapeutic approach for NAFLD treatment.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wu H, Xu X, Zheng A, et al. TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. Hepatology. 2021. PMID: 33713358. doi:10.1002/hep.31801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。